News & Updates

Show Multimedia Only

Long-term use of mirikizumab does not raise new safety signals

11 Jan 2026 by

A recent study has demonstrated the long-term safety of mirikizumab in patients with moderate to severe active ulcerative colitis (UC), with no new significant safety concerns.

Long-term use of mirikizumab does not raise new safety signals

11 Jan 2026

Synbiotics beneficial to older adults with diabetes

11 Jan 2026

A multi-species synbiotic preparation appears to improve outcomes in older patients with type 2 diabetes mellitus and high cardiovascular risk, according to a study.

Synbiotics beneficial to older adults with diabetes

11 Jan 2026

Patient fatigue flags risk of toxicity from cancer treatment

10 Jan 2026 by

Patient fatigue reported before the initiation of cancer treatment appears to be associated with an increased risk of subsequent treatment-related adverse events, according to new research.

Patient fatigue flags risk of toxicity from cancer treatment

10 Jan 2026

Long-term aspirin use may raise HF incidence

10 Jan 2026

Long-term use of aspirin tends to increase the risk of heart failure (HF) in individuals without cardiovascular disease (CVD), suggests a recent study.

Long-term aspirin use may raise HF incidence

10 Jan 2026

Subcutaneous anifrolumab beneficial in systemic lupus erythematosus

10 Jan 2026

Administering anifrolumab shots in addition to standard therapy is safe and yields clinically meaningful benefits in moderate to severe systemic lupus erythematosus, according to the phase III TULIP-SC trial.

Subcutaneous anifrolumab beneficial in systemic lupus erythematosus

10 Jan 2026

SGLT2 inhibitors improve cardiovascular, hepatic outcomes in MASLD patients

09 Jan 2026

In addition to improving glycaemic control, the use of SGLT2 inhibitors also appears to reduce mortality, hospitalization, cardiovascular events, and liver complications in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), according to a study.

SGLT2 inhibitors improve cardiovascular, hepatic outcomes in MASLD patients

09 Jan 2026

T-DXd plus RT shows promise in management of metastatic breast cancer

09 Jan 2026

Combination treatment with trastuzumab deruxtecan (T-DXd) and radiation therapy (RT) may improve clinical outcomes, without compromising safety, in patients with HER2-positive and HER2-low metastatic breast cancer, reveals a study.

T-DXd plus RT shows promise in management of metastatic breast cancer

09 Jan 2026

Ropeginterferon alfa-2b fares well for ET in ROP-ET trial

09 Jan 2026 by

The results from the phase III ROP-ET trial demonstrate the potential of ropeginterferon alfa-2b (ropeg) for the treatment of essential thrombocythaemia (ET) across all risk levels in patients who are ineligible for standard cytoreduction.

Ropeginterferon alfa-2b fares well for ET in ROP-ET trial

09 Jan 2026

Intravenous thrombolysis safe, beneficial for stroke patients with recent DOAC use

09 Jan 2026

In the treatment of acute ischaemic stroke in patients with recent direct oral anticoagulant (DOAC) use, intravenous thrombolysis appears to be safe and is associated with improvements in functional outcomes, according to a study.

Intravenous thrombolysis safe, beneficial for stroke patients with recent DOAC use

09 Jan 2026

IV iron lowers mortality risk in anaemics

09 Jan 2026 by

A retrospective study spanning 25 years has shown that intravenous (IV) iron therapy in hospitalized patients with iron-deficiency anaemia and acute infections is associated with a lower risk of death.

IV iron lowers mortality risk in anaemics

09 Jan 2026

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Long-term use of mirikizumab does not raise new safety signals

Long-term use of mirikizumab does not raise new safety signals

Synbiotics beneficial to older adults with diabetes

Synbiotics beneficial to older adults with diabetes

Patient fatigue flags risk of toxicity from cancer treatment

Patient fatigue flags risk of toxicity from cancer treatment

Long-term aspirin use may raise HF incidence

Long-term aspirin use may raise HF incidence

Subcutaneous anifrolumab beneficial in systemic lupus erythematosus

Subcutaneous anifrolumab beneficial in systemic lupus erythematosus

SGLT2 inhibitors improve cardiovascular, hepatic outcomes in MASLD patients

SGLT2 inhibitors improve cardiovascular, hepatic outcomes in MASLD patients

T-DXd plus RT shows promise in management of metastatic breast cancer

T-DXd plus RT shows promise in management of metastatic breast cancer

Ropeginterferon alfa-2b fares well for ET in ROP-ET trial

Ropeginterferon alfa-2b fares well for ET in ROP-ET trial

Intravenous thrombolysis safe, beneficial for stroke patients with recent DOAC use

Intravenous thrombolysis safe, beneficial for stroke patients with recent DOAC use

IV iron lowers mortality risk in anaemics

IV iron lowers mortality risk in anaemics